A Phase II study of the tumour-targeting human F16IL2 monoclonal antibody-cytokine fusion protein in combination with paclitaxel versus paclitaxel alone in patients with Merkel cell carcinoma
Latest Information Update: 07 Feb 2020
At a glance
- Drugs F16 IL2 fusion protein (Primary) ; Paclitaxel
- Indications Cancer metastases; Merkel cell carcinoma
- Focus Biomarker; Therapeutic Use
- Acronyms IMMOMEC
- Sponsors Philogen
- 07 Feb 2020 Status changed from recruiting to discontinued.
- 07 Feb 2020 This trial has been discontinued in Poland
- 06 Oct 2018 This trial has been discontinued in Spain.